Page 26 - Clinical Program News Today

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights News provided by Share this article Share this article PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended Decembe...

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients - 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1] - All ranked secondary endpoints were met[1] - These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2] - Safety results were consistent wi...

Rowan County health director resigns, takes position at Coastal county Nina Oliver (Source: WBTV) By WBTV Web Staff | February 16, 2021 at 7:22 PM EST - Updated February 16 at 9:00 PM ROWAN COUNTY, N.C. (WBTV) - The Rowan County health director is stepping down to take a position in another county. Nina Oliver told WBTV she has submitted her resignation. She will take a health director position in Carteret County, near the North Carolina coast. The Rowan County Board of Health is appoint...

Georgia Southern University Newsroom Home > Awards and Recognition > Georgia Southern Counseling Center staff win big at Georgia College Counseling Association awards Georgia Southern Counseling Center staff win big at Georgia College Counseling Association awards February 16, 2021 Licensed professional counselor Nikita Robinson and staff psychologist Mark Taracuk, Ph.D. Georgia Southern University licensed professional counselor Nikita Robinson and staff psychologist Mark Taracuk...

 E-Mail (Boston)-- While a number of topical products designed to reduce the occurrence of sexually transmitted infections have been tested with largely disappointing results, researchers at Boston University School of Medicine (BUSM), Alpert Medical School of Brown University and Mapp Biopharmaceutical have now found that MB66, a vaginal film product containing monoclonal antibodies against human immunodeficiency virus-type 1 (HIV-1) and herpes simplex viruses types 1 and 2 (HSV-1 and 2), is ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim ... Cassava Sciences, Inc.February 2, 2021 GMT - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 - - Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program - AUSTIN, Texas, Feb. 02, 2021 (GLOBE ...

Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at 12:15 p.m. MST. The presentation will provide an update on ...

Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a review of corporate highlights from 2020 and outlined anticipated key clinical program milestones for 2021. While 2020 was marked by tremendous challenges due to the COVID-19 pandemic...

NextCure Provides Updates on NC318 Clinical Program NextCure Provides Updates on NC318 Clinical Program BELTSVILLE, Md., Dec. 17, 2020 — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target. ...

ABBVie today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 … ABBVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads...